Literature DB >> 23203407

Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma.

Chuang Zhou1, Hai-Jun Zhou, Xiao-Fei Zhang, Li-Li Lou, Qing-Hai Ye, Yan Zheng, Ji Wang, Hai-Tao Zhu, Qiong-Zhu Dong, Hu-Liang Jia, Wen-Wei Zhu, Lei Guo, Yue Zhao, Dong-Mei Gao, Lun-Xiu Qin.   

Abstract

BACKGROUND: Presurgery serum osteopontin (OPN) level has been demonstrated to correlate to tumor recurrence and survival of hepatocellular carcinoma (HCC) patients. This study investigated the postoperative dynamic changes of serum OPN level and its clinical significance in HCC patients.
METHODS: Presurgery serum OPN levels were measured by enzyme-linked immunosorbent assay in cohort A of 179 HCC patients and were compared with the multiple controls including different kinds of liver diseases and healthy individuals. In cohort B of 110 patients with resectable HCCs, besides preoperative assays, serum OPN was monitored at 1 week, 1, and ≥2 months after operation.
RESULTS: The baseline presurgery serum OPN of HCC patients was significantly higher than that of the patients with the other kinds of liver diseases (p < 0.0001). The prognostic values of presurgery serum OPN level in HCC patients were further confirmed. The postsurgery OPN levels were significantly elevated within 1 week after HCC resection, then decreased at 1 month and reached the nadir later than 2 months after operations. It increased again at the time of tumor recurrence, then declined after the second removal of recurrent HCCs. Moreover, postoperative OPN in α-fetoprotein-negative and -positive HCC patients had the same changing pattern; it only correlated to liver function and C-reactive protein level.
CONCLUSIONS: After a transient fluctuation, serum OPN levels significantly decrease after curative resection of HCCs. Postoperative serum OPN could serve as a surrogate serologic biomarker for monitoring treatment response and tumor recurrence after HCC resection, including α-fetoprotein-negative ones.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23203407     DOI: 10.1245/s10434-012-2749-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.

Authors:  Matthew A C Zapf; Anai N Kothari; Cynthia E Weber; Matthew L Arffa; Phillip Y Wai; Joseph Driver; Gopal N Gupta; Paul C Kuo; Zhiyong Mi
Journal:  Surgery       Date:  2015-07-17       Impact factor: 3.982

Review 3.  Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies.

Authors:  Lunxiu Qin
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

4.  RAN GTPase and Osteopontin in Pancreatic Cancer.

Authors:  Shivam Saxena; Ankit Gandhi; Pei-Wen Lim; Daniel Relles; Konrad Sarosiek; Christopher Kang; Galina Chipitsyna; Jocelyn Sendecki; Charles J Yeo; Hwyda A Arafat
Journal:  Pancreat Disord Ther       Date:  2013-04-01

5.  Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.

Authors:  Felicitas Strehlow; Sandra Bauer; Peter Martus; Michael Weller; Patrick Roth; Uwe Schlegel; Sabine Seidel; Carmen Scheibenbogen; Agnieszka Korfel; Stephan Kreher
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

6.  Post-operative plasma osteopontin predicts distant metastasis in human colorectal cancer.

Authors:  Lui Ng; Timothy Ming-Hun Wan; Colin Siu-Chi Lam; Ariel Ka-Man Chow; Sunny Kit-Man Wong; Johnny Hon-Wai Man; Hung-Sing Li; Nathan Shiu-Man Cheng; Ryan Chung-Hei Pak; Alvin Ho-Kwan Cheung; Thomas Chung-Cheung Yau; Oswens Siu-Hung Lo; Dominic Chi-Chung Foo; Jensen Tung-Chung Poon; Ronnie Tung-Ping Poon; Roberta Wen-Chi Pang; Wai-Lun Law
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

7.  C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.

Authors:  Ying Zhu; Xiao-Mei Gao; Jing Yang; Da Xu; Yu Zhang; Ming Lu; Ze Zhang; Yuan-Yuan Sheng; Jian-Hua Li; Xin-Xin Yu; Yan Zheng; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Cancer Sci       Date:  2018-02-13       Impact factor: 6.716

Review 8.  Role of Osteopontin in Liver Diseases.

Authors:  Yankai Wen; Seogsong Jeong; Qiang Xia; Xiaoni Kong
Journal:  Int J Biol Sci       Date:  2016-08-06       Impact factor: 6.580

9.  SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma.

Authors:  Takayuki Kawai; Kentaro Yasuchika; Takamichi Ishii; Yuya Miyauchi; Hidenobu Kojima; Ryoya Yamaoka; Hokahiro Katayama; Elena Yukie Yoshitoshi; Satoshi Ogiso; Sadahiko Kita; Katsutaro Yasuda; Ken Fukumitsu; Junji Komori; Etsuro Hatano; Yoshiya Kawaguchi; Shinji Uemoto
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

10.  A Novel Post-Operative ALRI Model Accurately Predicts Clinical Outcomes of Resected Hepatocellular Carcinoma Patients.

Authors:  Minjun Liao; Jiarun Sun; Qifan Zhang; Cuirong Tang; Yuchen Zhou; Mingrong Cao; Tao Chen; Chengguang Hu; Junxiong Yu; Yangda Song; Meng Li; Weijia Liao; Yuanping Zhou
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.